NCT02983604 - GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions

Advanced Estrogen Receptor Positive HER2- Breast Cancer

Interventions

DRUG

GS-5829

Tablet(s) administered orally once daily

DRUG

Exemestane

25 mg tablet administered orally once daily (or in accordance with locally approved labeling)

DRUG

Fulvestrant

"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."

Trial Locations (6)

37203

The Sarah Cannon Research Institute, Nashville

55407

Allina Health, Virginia Piper Cancer Institute, Minneapolis

77030

Baylor University Medical Center, Houston

94305

Stanford Women's Cancer Center, Stanford

99208

Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane

02215

Dana Farber Cancer Institute, Boston